Regeneron Reports Positive Results of Evinacumab in P-III Study for Homozygous Familial Hypercholesterolemia

 Regeneron Reports Positive Results of Evinacumab in P-III Study for Homozygous Familial Hypercholesterolemia

Regeneron Reports Positive Results of Evinacumab in P-III Study for Homozygous Familial Hypercholesterolemia

Shots:

  • The P-III study involves assessing of Evinacumab vs PBO in patients with homozygous familial hypercholesterolemia (HoFH) for 24wks.
  • The P-III study results: reduction in LDL cholesterol (49% vs 47%); LDL cholesterol levels<100mg/dL (47% vs 23%); similar reduction in LDL cholesterol level in “negative/negative” patients; reduction in apolipoprotein B (ApoB), non-HDL cholesterol and total cholesterol; AEs (66% vs 81%)
  • Evinacumab is an investigational mAb targeting ANGPTL3, currently being evaluated in P-III study for HoFH and P-II studies for refractory hypercholesterolemia and severe hypertriglyceridemia and has received the US FDA’s BT designation for the treatment of hypercholesterolemia in patients with HoFH in 2017

Click here to­ read full press release/ article | Ref: Regeneron | Image: High Point University

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post